Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | £26 | £17 | £26 | £23 |
| - Cash | £2 | £1 | £1 | £1 |
| + Debt | £6 | £2 | £5 | £7 |
| Enterprise Value | £31 | £18 | £30 | £29 |
| Revenue | £12 | £12 | £11 | £11 |
| % Growth | 5% | 3.3% | 3.2% | – |
| Gross Profit | £6 | £5 | £5 | £5 |
| % Margin | 45.3% | 46.2% | 44.4% | 43.7% |
| EBITDA | £3 | £3 | £2 | £2 |
| % Margin | 21.2% | 25.2% | 19.9% | 21.7% |
| Net Income | £2 | £2 | £1 | £1 |
| % Margin | 14.9% | 14.3% | 13% | 12.4% |
| EPS Diluted | 4.1 | 3.77 | 3.31 | 3.06 |
| % Growth | 8.8% | 13.9% | 8.2% | – |
| Operating Cash Flow | £1 | £2 | £2 | £2 |
| Capital Expenditures | -£1 | -£0 | -£1 | -£0 |
| Free Cash Flow | -£0 | £1 | £1 | £2 |